Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 53.50
-0.20 (-0.37%)
At close: Dec 19, 2025
Basilea Pharmaceutica AG Revenue
Basilea Pharmaceutica AG had revenue of 103.96M CHF in the half year ending June 30, 2025, with 22.44% growth. This brings the company's revenue in the last twelve months to 236.21M, up 58.51% year-over-year. In the year 2024, Basilea Pharmaceutica AG had annual revenue of 208.54M with 32.30% growth.
Revenue (ttm)
236.21M
Revenue Growth
+58.51%
P/S Ratio
2.78
Revenue / Employee
1.31M
Employees
164
Market Cap
657.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
| Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
| Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
| Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
| Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
Basilea Pharmaceutica AG News
- 10 days ago - Basilea partners with Phare Bio to deploy generative AI for antibiotic discovery - Seeking Alpha
- 10 days ago - Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic - GlobeNewsWire
- 10 days ago - Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI - Business Wire
- 6 weeks ago - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea - GlobeNewsWire
- 3 months ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire
- 3 months ago - Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 - GlobeNewsWire
- 4 months ago - Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 4 months ago - Basilea Pharmaceutica AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha